Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Syngenta will acquire Massachusetts-based Conrad Fafard, which produces packaged plant-growing media for nonagricultural markets, for $133.5 million. Fafard had sales of $76 million in its last fiscal year.
Cognis has consolidated European production of its DSX "green" rheology additives at its site in Castellbisbal, near Barcelona. The site complements facilities in the U.S.
Athenagen and Zapaq, two private biopharmaceutical firms, are merging. Both companies are focused on neurological diseases and say the merger will help them succeed. Sanderling Ventures is the lead investor in both firms.
Qatar Fertiliser and Qatar Intermediate Industries are establishing Qatar Melamine Co., which will build a 60,000-metric-ton-per-year melamine plant in Qatar. Norwegian fertilizer maker Yara is participating through its 25% ownership of Qatar Fertiliser.
Dow Chemical has soldits Smithfield, R.I., biopharmaceutical plant to Alexion Pharmaceuticals, which will use it to manufacture Soliris, a treatment for a genetic blood disorder. Dow closed the plant in 2004.
Cardinal Health is the latest company to become a member of Roche's supply network for Tamiflu, the frontline treatment in the event of an avian flu pandemic. Cardinal Health will manufacture and package 75-mg hard-gelatin capsules of Tamiflu.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter